Clinical trials: Type1 Diabetes Mellitus
Type 1 Diabetes
Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients
This study was designed to determine which maintenance immunosuppressive agent, rapamycin or mycophenalate mofetil, resulted in better outcome in patients with type 1 diabetes and renal failure, who presented for a…
- Trial name
- NCT00533442
- Testing
- Rapamycin, Mycophenolate Mofetil, Tacrolimus
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- University of Miami
Healthy Volunteers, Diabetes Mellitus, Type 1
Evaluation of 18 F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass
Type 1 diabetes mellitus (T1DM) develops when there is impaired insulin production due to loss of insulin producing cells (beta cells).
- Trial name
- NCT02236754
- Testing
- 18 F-FP-DTBZ, PET Scanning
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Columbia University
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)
This is a randomized, active- and placebo-controlled, double-blind trial of MK-5160 in participants with Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM). This is a two-part trial, with three panels per part.
- Trial name
- NCT03095651
- Testing
- MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 1
A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar), both with insulin aspart (IAsp) as…
- Trial name
- SWITCH 1 (NCT02034513)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 99 sites in United States, Poland and 1 more
- Volunteers
- 501 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Assessment of a Decision Support Tool in Participants With Type 1 Diabetes
Type 1 diabetes (T1D) is a complex disease with a high risk of both hyper- and hypoglycemia which can lead to severe acute and chronic complications.
- Trial name
- NCT04428645
- Testing
- DailyDose Decision Support
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Oregon Health and Science University
Islet Transplantation in Diabetes Mellitus Type 1
Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation
The objective of this clinical trial was: to assess whether Reparixin leads to improved transplant outcome as measured by glycaemic control following intra-hepatic infusion of pancreatic islets in patients with Type 1 diabetes…
- Trial name
- REP0211 (NCT01817959)
- Testing
- Reparixin
- Where
- 9 sites in United States, Czechia and 3 more
- Volunteers
- 51 people
- Sponsor
- Dompé Farmaceutici S.p.A
Type 1 Diabetes
DIabetic Retinopathy Candesartan Trials.
The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients with retinopathy.
- Trial name
- DIRECT (NCT00252720)
- Testing
- candesartan
- Volunteers
- 1,850 people
- Sponsor
- AstraZeneca
Graft Rejection
Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
The purpose of this research study is to compare the effects of the two most commonly used anti-T cell induction agents(alemtuzumab and rabbit anti-thymocyte globulin) to prevent rejection in kidney and pancreas transplant…
- Trial name
- NCT00331162
- Testing
- Alemtuzumab, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Wake Forest University Health Sciences
Type 1 Diabetes Mellitus
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
The primary purpose of this study is to determine whether teplizumab (MGA031) infusions lead to greater reductions in insulin requirements in conjunction with near normal blood sugar control compared to placebo in patients…
- Trial name
- NCT00920582
- Testing
- Teplizumab Herold Regimen, Teplizumab 33.3% Herold Regimen, Teplizumab Curtailed Herold Regimen
- Where
- 118 sites in United States, Belgium and 14 more
- Volunteers
- 254 people
- Sponsor
- MacroGenics
Type 1 Diabetes Mellitus
Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control
The incorporation of continuous glucose sensors (CGS) into management of type 1 diabetes in adolescence could improve treatment outcomes.
- Trial name
- CGM-Teens (NCT00945659)
- Testing
- Continuous Glucose Sensor, Standard Care, CGS + Behavior Therapy
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Nemours Children's Clinic
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)
This is an active- and placebo-controlled, single-site, four-part trial of MK-1092 in healthy adult participants, in participants with type 1 diabetes mellitus (T1DM), and in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03170544
- Testing
- MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
IgA Nephropathy, CKD Associated With Type 1 Diabetes
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes…
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Trial name
- PHOENIX (NCT03366337)
- Testing
- Bardoxolone methyl capsules
- Where
- 30 sites in United States
- Volunteers
- 103 people
- Sponsor
- Biogen
Type 2 Diabetes
Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes
This study will evaluate the effects of impaired blood flow regulation on exercise. It will also determine whether the effects are more important in the heart or in the skeletal muscle tissue during exercise.
- Trial name
- InsITE (NCT00786019)
- Testing
- Exercise program, Ascorbic Acid (Vitamin C)
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Type 1 Diabetes Mellitus, Physical Activity
Physical Activity in Children With Type 1 Diabetes Study
This study aims to test the feasibility of a physical activity intervention called the Steps To Active Kids (STAK) programme in children aged 9 - 11 years with Type 1 Diabetes Mellitus (T1DM).
- Trial name
- NCT02144337
- Testing
- Steps To Active Kids (STAK) programme
- Where
- United Kingdom
- Volunteers
- 13 people
- Sponsor
- University of Nottingham
Type 1 Diabetes
Evaluation of The Postprandial Impact of Automated Priming Bolus for Full Closed Loop Insulin Delivery
The purpose of this study is to understand the impact of the automated priming boluses on the safety and feasibility of a new fully automated AP controller.
- Trial name
- Rocket-BPS (NCT05528770)
- Testing
- FCL+BPS, FCL
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Marc Breton
Type 1 Diabetes
Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D)
In this 2-year randomized clinical trial, we will implement and assess the impact of a behavioral/psychoeducational intervention to reduce diabetes distress and improve glycemic outcomes in adolescents and young adults, aged…
- Trial name
- NCT05413239
- Testing
- Psychoeducation to reduce diabetes distress and improve glycemic outcomes
- Where
- 2 sites in United States
- Volunteers
- 217 people
- Sponsor
- Joslin Diabetes Center
Diabetes Mellitus, Type 1
Adapting Diabetes Treatment Expert Systems to Patient in Type 1 Diabetes
This study is evaluate the superior efficacy of a Continuous Glucose Monitor (CGM)-based advisory system in Type 1 Diabetes Mellitus (T1DM), as compared to Sensor Augmented Mode (SAM) therapy, and with characterizing the impact…
- Trial name
- DSS-2 (NCT04443153)
- Testing
- Personalized Feedback, Decision Support System, Sensor Augmented Mode
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- University of Virginia
Type 1 Diabetes
Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®
This is an extension study to evaluate the safety and tolerability of long-term treatment with DiaPep277® and to determine the long-term treatment effect of DiaPep277® on parameters of metabolic control and on preservation of…
- Trial name
- DIA-AID 2 (NCT01898286)
- Testing
- DiaPep277®
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Andromeda Biotech Ltd.
Type 1 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin
Primary Objective: To compare the glucose control during treatment with a new formulation of insulin glargine and Lantus in adult participants with type 1 diabetes mellitus Secondary Objectives: To compare a new formulation of…
- Trial name
- NCT01658579
- Testing
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- Sanofi
Type I Diabetes Mellitus
Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus
The purpose of this study is: to assess clinical efficacy of Subetta in the combined treatment of type I diabetes mellitus; to assess safety of Subetta in the combined treatment of type I diabetes mellitus.
- Trial name
- NCT01868594
- Testing
- Subetta
- Where
- 15 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Materia Medica Holding